CACNA1H and prostate carcinoma: In particular, there is pharmacological evidence of a contribution from T-type calcium channels, including, specifically, Cav3.2, to the proliferative activity of prostate cancer cells in vitro and to cancer progression in xenograft experiments [148,149].